Condition
Hip Osteoarthritis: Options and What the Evidence Actually Shows
Hip OA is common and often leads toward arthroplasty — but many patients spend years on a nonoperative ladder first.
Anatomy and clinical context
Femoral head and acetabular cartilage loss produce groin pain and limited rotation. Radiographic severity guides timing more than marketing claims.
Weight management and PT matter. Injections may reduce symptoms temporarily.
Illustration of the hip joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
PT, activity modification, weight management, oral meds.
- Step 2
Injections
Image-guided corticosteroid or orthobiologic injectates.
- Step 3
Surgery
Total hip arthroplasty for end-stage disease.
Where cell therapy fits
Hip OA injectate evidence is less mature than knee. Total hip replacement remains one of the most successful operations in medicine when indicated.
- Do not delay clearly indicated arthroplasty chasing unproven injectates.
- Same-day products face dose/potency limits.
- Banking is about future autologous supply — complementary to, not instead of, good surgical timing.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Stempeucel
Approved product (India) · Regulatory approval (2020)
Culture-expanded MSC product approved in India — example of dose-enabled products showing clinical pathway beyond same-day unexpanded injectates.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.